Amgen (AMGN) stock experienced a decline of 0.72% amidst differing brokerage ratings, insider selling, and fluctuations in institutional investor positions. 

The decline in Amgen's stock price can be attributed to a combination of overall market performance, insider selling activity, and lackluster investor sentiment reflected in the mixed recommendations from analysts.

Amgen (AMGN) stock experienced a decline of 0

Amgen's (AMGN) stock increased by 0.75% last night due to its inclusion in the monthly dividend calendar favored by family offices seeking reliable income streams, highlighting its reputation as a stable, dividend-paying company amidst ongoing market volatility.

Amgen's (AMGN) stock increased by 0

Amgen (AMGN) stock decreased by 0.22% amid ongoing changes in institutional investment positions, with several funds acquiring or adjusting their stakes in the company, reflecting market uncertainty. The decline could also be attributed to broader market sentiment following recent earnings reports and price target adjustments from brokerages, including a neutral rating from Cantor Fitzgerald.

Amgen (AMGN) stock decreased by 0

Amgen (AMGN) stock decreased by 0.22% amid positive results for AstraZeneca's gefurulimab in treating generalized myasthenia gravis, potentially signaling increased competition for Amgen's own myasthenia gravis treatments.

Amgen (AMGN) stock rose by 1.15% due to positive developments in its branded drug sales, promising clinical trial results for its pipeline products, and ongoing investments in domestic manufacturing, despite facing concerns over tariffs and drug pricing pressures.

Amgen (AMGN) stock rose by 1

Amgen (AMGN) stock declined by 1.17% due to a general market trend affecting dividend stocks, even though it has shown strong revenue growth and earnings performance in recent quarters.

Amgen (AMGN) stock declined by 1

Amgen (AMGN) stock fell by 1.17% following a mix of recent analyst updates, including UBS lowering its target price, indicating cautious sentiment in the market despite an earnings estimate increase from William Blair.

Amgen (AMGN) stock fell by 1

Amgen (AMGN) stock rose by 2.23% following an upgrade in earnings estimates for FY2026 by William Blair, which increased its forecast from $21.62 to $21.67 per share, reflecting a positive outlook for the company's financial performance.

Amgen (AMGN) stock rose by 2

The article discusses a report indicating that Representative Cliff Bentz purchased Amgen (AMGN) stock, which may be contributing to a recent increase in the stock's value, as it was up 1.3% last night. 

The stock may have gone up due to positive investor sentiment surrounding insider purchases, which can indicate confidence in the company's future performance.

The article discusses a report indicating that Representative Cliff Bentz purchased Amgen (AMGN) sto

Amgen (AMGN) stock rose 1.3% last night, reflecting strong investor confidence in the company's robust growth potential and historical performance in the biotechnology sector. 

The stock increase may be attributed to positive market sentiment surrounding the company’s innovations, earnings reports, or industry developments.

Amgen (AMGN) stock rose 1

Amgen (AMGN) stock rose by 1.3% due to positive investor sentiment linked to increased activity and investments in the biotech sector, particularly in the context of recent expansions announced by companies like Amgen in the tech and healthcare space.

The article discusses Merck's acquisition of Verona Pharma for approximately $10 billion, part of a broader trend of U.S. pharmaceutical companies seeking to diversify their portfolios through acquisitions. Amgen's (AMGN) stock was down by 0.16%, which may be attributed to investors' reactions to the ongoing consolidation in the pharmaceutical industry, as competition and market dynamics shift with major deals like Merck's affecting sentiment towards smaller biotechs and their associated stocks.

The article discusses Merck's acquisition of Verona Pharma for approximately $10 billion, part of a 

Amgen (AMGN) stock rose 1.38% amid a mixed market reaction to President Trump's announcement of impending tariffs on pharmaceuticals, suggesting investor optimism despite potential challenges. 

The increase in Amgen's stock can be attributed to a broader positive sentiment in the pharmaceutical sector, even as the market reacted negatively to the proposed tariffs; investors may be betting on Amgen's resilience and potential for negotiation or adaptation to new tariff regulations.

Amgen (AMGN) stock rose 1.38% likely due to its position as a stable healthcare company within a generally sluggish market, and its strong fundamentals, including a solid market cap and dividend yield, contributing to investor confidence despite sector-wide concerns over Medicaid cuts.

Amgen (AMGN) stock rose by 1.38% amidst a mixed market where other stocks faced declines, likely due to investor sentiment remaining optimistic about potential negotiations arising from President Trump's extension of the tariff deadline to August 1, which gave markets more time to assess impacts on the pharmaceutical sector.

Amgen (AMGN) stock rose by 0.47% likely due to positive analyst recommendations and upgraded price targets from several financial institutions, reflecting investor confidence in the company's robust earnings performance and growth potential.

Amgen (AMGN) stock rose by 0

Amgen (NASDAQ: AMGN) stock rose by 2.18% due to positive quarterly earnings results that exceeded analysts' expectations, increased institutional investments, and favorable analyst ratings on the stock.

Amgen (NASDAQ: AMGN) stock rose by 2

Amgen (AMGN) stock rose by 2.18% last night, primarily due to increased investor confidence driven by AbbVie's successful strategic acquisitions and its anticipated revenue growth, contrasting sharply with the declining sales of its flagship product, Humira.

Amgen (NASDAQ: AMGN) stock rose 4.05% recently due to increased institutional investment activity and positive earnings performance, with the company exceeding analyst expectations for both earnings per share and revenue in its last reported quarter.

Amgen (NASDAQ: AMGN) stock rose 4

Amgen (AMGN) stock rose 4.05% likely due to positive sentiments surrounding the European Commission's efforts to streamline biotech regulations and address funding gaps as Belgium's biotech sector calls for comprehensive reforms to reclaim its leadership in the industry, which could improve the investment climate for biotech companies.

Amgen (AMGN) stock rose 4

Amgen (AMGN) stock was down 0.71% as it faces challenges amidst a competitive biotechnology landscape and growing concerns about its pipeline and market position relative to other companies like Merck, which poses more strategic advancements in diversifying its revenue stream beyond its leading drug, Keytruda.

Amgen (AMGN) stock was down 0

Amgen (NASDAQ:AMGN) stock fell by 0.44% despite having its "outperform" rating reaffirmed, likely due to mixed analyst ratings and target price adjustments, along with the sell-off of shares by insiders, which may have increased investor concerns.

Amgen (NASDAQ:AMGN) stock fell by 0

Amgen (AMGN) stock rose by 1.03% due to increased institutional investment, as several hedge funds boosted their stakes in the company.

Amgen (AMGN) stock rose 1.03% following a neutral rating reaffirmation by Cantor Fitzgerald and positive quarterly earnings that exceeded expectations, driving investor confidence in the company's performance.

Amgen (AMGN) stock rose 1.85% likely due to its overall strong performance, moderate valuation, and continued confidence in its long-acting obesity drug MariTide despite challenges in clinical trials.

Amgen Inc. (NASDAQ: AMGN) shares fell by 5.7% to $272.88 following the release of disappointing full results from part one of its phase two study of MariTide, the company's investigational obesity treatment.

Amgen Inc

Amgen (AMGN) stock dropped by 5.84% due to market reactions, likely influenced by factors including recent company announcements, investor sentiment, or broader market trends, although the article primarily focuses on the appointment of a new CFO at Galapagos NV and its implications.

Amgen (AMGN) stock dropped by 5

Amgen (AMGN) stock decreased by 0.14% primarily due to broader market pressures or negative investor sentiment, as the article focuses on the comparison between small-cap medical companies Verastem and Ensysce Biosciences rather than on specific reasons for Amgen's stock movement.

Amgen (NASDAQ: AMGN) stock declined by 1.86% following a significant reduction in holdings by Elevation Point Wealth Partners LLC, which sold 73.7% of its shares in the first quarter, indicating potential concerns about investor confidence and market sentiment.

Amgen (NASDAQ: AMGN) stock declined by 1

Amgen (AMGN) stock declined by 1.86% due to market reactions possibly connected to broader industry trends or specific news affecting biotech stocks, although the article primarily discusses Cardiff Oncology's executive appointment and upcoming clinical data rather than directly attributing the drop to specific events related to Amgen.

Amgen (NASDAQ:AMGN) stock fell by 0.7% due to the mixed reactions following analyst reports adjusting earnings estimates, despite Amgen having reported better-than-expected quarterly results. The potential reason for the decline may be market adjustments to the EPS estimates that still lag behind consensus, as well as overall market sentiment reflected in the ratings from various analysts.

Amgen (AMGN) stock decreased by 0.7% last night, potentially due to the publication of findings from the IRONMAN trial which showed that intravenous iron therapy did not significantly improve outcomes in heart failure patients across different age groups, which might negatively impact investor expectations regarding future sales of related therapies.

Amgen (AMGN) stock rose by 1.88% following positive earnings results for the previous quarter which exceeded analysts' expectations, along with Cantor Fitzgerald's optimistic FY2026 earnings per share estimate of $21.58, which likely boosted investor confidence.

Amgen's stock (NASDAQ: AMGN) fell by 0.12% after Senior Vice President Rachna Khosla sold 1,500 shares, reducing her position by 15.52%, which may have raised concerns among investors about insider confidence in the company.

Amgen's stock (NASDAQ: AMGN) fell by 0

Amgen (AMGN) stock rose by 0.03% due to positive developments related to ongoing research and therapeutic trials targeting adherent invasive Escherichia coli (AIEC), which are linked to Crohn's disease, suggesting potential future impacts on health outcomes and market confidence.

Amgen (AMGN) stock fell by 0.88% as part of broader market declines influenced by concerns over potential economic slowdowns and trade issues resulting from U.S. tariff negotiations.

Amgen (AMGN) stock fell by 0

The article discusses a meta-analysis that evaluates the long-term effectiveness of P2Y12 inhibitor monotherapy compared to aspirin monotherapy for patients after percutaneous coronary intervention (PCI), showing that P2Y12 inhibitors significantly lower the risk of major adverse cardiac and cerebrovascular events without increasing the risk of major bleeding.

Amgen (AMGN) stock may have declined by -0.88% due to a variety of factors, which could include market reactions to recent clinical trial results, shifts in the healthcare landscape, or broader economic conditions affecting investor sentiment.

The article discusses a meta-analysis that evaluates the long-term effectiveness of P2Y12 inhibitor 

The article discusses Amgen (AMGN) stock's recent 0.38% rise, highlighting Eli Lilly's (LLY) position in the obesity drug market and the competitive landscape. Amgen's stock likely saw an increase due to overall positive market conditions and investor confidence in the biotechnology sector, particularly as companies like LLY and others in the obesity treatment space gain attention, suggesting a bullish sentiment towards pharmaceutical stocks.

The article discusses Amgen (AMGN) stock's recent 0

Amgen (AMGN) stock rose by 1.85% due to positive investor sentiment and market conditions, potentially influenced by developments in partnerships and growth opportunities in the biopharmaceutical sector associated with its collaborations with companies like Entera Bio and Aligos Therapeutics.

Amgen (AMGN) stock saw a rise of 2.87% likely due to positive investor sentiment as it engages in collaborations and developments in innovative therapies, including partnerships with TScan Therapeutics and advancements in oncology treatments.

Amgen (AMGN) stock saw a rise of 2

Amgen Inc. (AMGN) stock declined by 0.09% following a downgrade in Q2 2025 earnings per share estimates by Zacks Research, which lowered its forecast from $5.22 to $5.20, impacting investor sentiment.

Amgen's stock (AMGN) rose by 0.21% following mixed phase 2 data for its weight loss candidate, as the company has other promising drug developments in its pipeline that remain attractive to investors despite competition from Viking Therapeutics.

Amgen's stock (AMGN) rose by 0

Amgen's (AMGN) stock declined by 1.33% due to investor concerns surrounding the potential completion of a significant acquisition transaction, which may lead to volatility and uncertainty in the stock's performance.

Amgen's (AMGN) stock declined by 1

Amgen (AMGN) stock decreased by 0.3% likely due to market reactions to developments surrounding VERAXA Biotech AG's recent announcements and leadership appointments, which could be viewed as competitive moves in the oncology space given Amgen's ongoing focus in this area.

Amgen (AMGN) stock dipped by 0.3% amidst news about the appointment of Dr. Rick Austin as Chief Scientific Officer at VERAXA Biotech, a company that has potential implications for the oncology field, raising concerns regarding Amgen's competitive position in cancer therapies.

Amgen (AMGN) stock dipped by 0

Amgen (AMGN) stock rose by 1.26% last night, likely due to positive sentiment stemming from favorable comparisons between pharmaceutical companies, particularly highlighting Aadi Bioscience's perceived growth potential as more favorable than its competitor, UCB, which could influence investor confidence in Amgen as a key player in the sector.

Amgen (AMGN) experienced a 1.26% increase in stock price, partly due to positive quarterly earnings that surpassed expectations, with a reported EPS of $4.90 compared to the consensus estimate of $4.18, as well as a strong revenue growth of 9.4% year-over-year.

Amgen (AMGN) experienced a 1

Amgen (AMGN) stock rose by 1.26% possibly due to positive market sentiment or developments related to its collaborations, particularly with TScan Therapeutics, which may enhance investor confidence in future growth prospects.

Amgen (AMGN) stock increased by 1.26% due to positive market sentiment, although Piper Sandler lowered its price target for the company.

Amgen (AMGN) stock increased by 1

Amgen Inc. (AMGN) stock fell by 3.02% as analysts maintain a consensus "Hold" rating with varying price targets and amid news of a significant insider stock sale. The decline in stock price may be attributed to the mixed ratings from analysts and the recent sell-off by an executive, which can raise concerns about future performance and investor sentiment.

Amgen (AMGN) stock rose 3.35% after positive quarterly earnings results exceeded analyst expectations, despite a downgrade in its rating from "strong-buy" to "buy" by StockNews.com and a variety of mixed assessments from other research firms.

Amgen (AMGN) stock rose 3

Amgen (AMGN) stock rose by 3.35% following positive interim data from CytomX Therapeutics regarding their CX-2051 drug, which demonstrated a 28% confirmed response rate in a study involving patients with advanced colorectal cancer.

Amgen (AMGN) stock rose by 3

Amgen (AMGN) stock rose 3.35% following President Trump's executive order aimed at lowering drug prices, as analysts suggested the order would face significant legal challenges, reducing investor fears about its immediate impact on the pharmaceutical sector.

Amgen (AMGN) stock rose 3.35% following the positive interim clinical data announcement from CytomX Therapeutics regarding their CX-2051 antibody-drug conjugate, indicating significant potential for treatment in advanced colorectal cancer and boosting investor confidence in Amgen's collaboration with CytomX.

Amgen (AMGN) stock fell by 2.28% despite an analyst upgrading its price target, indicating a potential upside, likely due to mixed market sentiment and profit-taking following recent insider stock sales and fluctuating ratings from various research firms.

Amgen (AMGN) stock fell by 2

Amgen (AMGN) stock increased by 2.0% despite VP Matthew C Busch's recent insider sale of 1,000 shares, likely due to positive investor sentiment or broader market trends.

Amgen (AMGN) stock increased by 2

Amgen (AMGN) stock has decreased by 0.41% due to a combination of mixed analyst ratings and price target adjustments, including reductions from UBS Group and others, despite positive quarterly earnings that exceeded expectations.

Amgen (AMGN) stock has decreased by 0

Amgen (AMGN) stock declined by -0.41% amid market fluctuations, potentially influenced by broader sector performances and varying trading volumes.

Amgen (AMGN) stock declined by -0

Amgen (AMGN) stock fell by 0.41% after receiving mixed ratings from analysts, despite reporting strong quarterly earnings that surpassed expectations. The decline may be attributed to analysts maintaining neutral or hold ratings while adjusting target prices downward, as well as insider selling activity, which may have raised concerns among investors.

The article discusses a clinical trial evaluating the safety and preliminary effectiveness of AMG 404, a monoclonal antibody targeting PD-1 in advanced solid tumors, and notes that Amgen (AMGN) stock fell by 0.9%, likely due to investor concerns over the trial's outcomes and the potential for regulatory uncertainty surrounding the new treatment.

The article discusses a clinical trial evaluating the safety and preliminary effectiveness of AMG 40

Amgen (AMGN) shares fell 2.45% last night despite a strong start to 2025, likely due to overall market conditions affecting stock performance.

Amgen (AMGN) shares fell 2

Amgen (AMGN) stock rose by 1.93% due to positive market sentiment potentially fueled by developments in the biopharmaceutical sector, particularly Aclaris Therapeutics' appointment of Dr. Jesse Hall as Chief Medical Officer, which suggests advancements in immuno-inflammatory treatment innovations that could benefit associated companies like Amgen.

Amgen (AMGN) stock rose by 0.8% last night, likely due to positive investor sentiment driven by ongoing developments in the biotechnology sector, as reflected in the strong performances and favorable analyst ratings of related companies like Eagle Pharmaceuticals and IDEAYA Biosciences.

Amgen (AMGN) stock rose 0.36% last night, likely due to positive earnings expectations from analysts, including a forecast of $20.50 per share for FY2025 by Cantor Fitzgerald, and favorable ratings and price target adjustments from several other investment firms.

Amgen (AMGN) stock rose 0

Amgen (AMGN) stock rose 0.7% following Cantor Fitzgerald's initiation of coverage with a "neutral" rating and a price target of $305, indicating potential upside, amidst other analysts adjusting their ratings and price targets. 

The stock's increase can be attributed to positive analyst coverage and potential price target adjustments reflecting investor confidence in future growth.

Amgen (AMGN) stock declined by 0.18% primarily due to concerns over looming patent expirations that could negatively impact profits, as noted by ETF manager Michael Taylor, who chooses to avoid investing in Amgen and similar biotech firms.

Amgen (AMGN) stock declined by 0

Amgen (AMGN) stock recently dropped by 0.18% primarily due to concerns about economic policies under President Trump's administration, particularly tariffs that are raising costs for consumers and creating uncertainty in the market, negatively impacting business confidence and growth projections.

Amgen (AMGN) stock recently dropped by 0

The article reports that Amgen (AMGN) stock fell by 1.3% recently, but it does not provide details on the reasons for the decline. 

The decline in Amgen's stock could be attributed to various factors, including market conditions, investor sentiment, or company-specific news, although these specific reasons are not mentioned in the provided content.

The article reports that Amgen (AMGN) stock fell by 1

Amgen (AMGN) stock fell by 1.89% due to mixed analyst ratings and recent insider selling activities, coupled with ongoing concerns over the company's earnings outlook and market performance.

Amgen (AMGN) stock fell by 4.29% likely due to the looming Medicaid cuts, which could significantly impact revenue for healthcare providers, including those providing care that Amgen's products may support, thereby raising concerns about future profitability.

Amgen (AMGN) stock fell by 4

Amgen (AMGN) stock dropped 4.29%, despite an increased price target from UBS Group, likely due to combined effects of insider selling and fluctuating investor sentiment as analysts have mixed ratings on the stock, indicating uncertainty in the market.

Amgen (AMGN) stock dropped 4

Amgen Inc. (AMGN) shares fell by 1.8% to $289.09, contributing to a monthly decline of 9.34%, despite a yearly increase of 6.93%, likely due to concerns over its short-term performance.

Amgen (AMGN) stock declined by 0.4% to $305.50, reflecting a 3.50% decrease over the past month despite a 13.95% increase over the past year, likely due to concerns regarding its short-term performance.

The article discusses Coherus BioSciences' announcement of the repurchase of $170 million in convertible notes pending the divestiture of its UDENYCA franchise, but does not directly address the reasons for the decline in Amgen's (AMGN) stock, which fell by 1.49%. However, it can be inferred that market reactions to developments in related companies, such as Coherus BioSciences, or broader industry news, may have impacted Amgen's stock performance.

The article discusses Coherus BioSciences' announcement of the repurchase of $170 million in convert

Amgen (AMGN) stock rose by 1.5% amid a broader market rebound on concerns over President Trump's impending tariff announcements, which have led investors to rotate into more stable sectors such as healthcare. 

The increase in Amgen's stock can be attributed to investors seeking refuge in healthcare and consumer staples amidst the uncertainties surrounding trade tensions and inflation risks.

Amgen (AMGN) stock increased by 0.02% as it was identified as one of the top pharmaceutical stocks to watch due to high trading volumes, reflecting investor interest in the biotech sector amid a broader focus on pharmaceutical companies engaged in significant drug development and healthcare innovations.

Amgen (AMGN) stock increased by 0

Amgen (AMGN) stock was down 0.37% likely due to broader market trends or specific company performance indicators affecting investor sentiment, although the article primarily discusses Alvotech’s positive financial results and ongoing developments rather than directly linking to Amgen's stock movement.

Amgen (AMGN) stock was down 0.37% due to market fluctuations potentially influenced by investor sentiment following Alvotech's recent financial performance and developments in the biotech sector.

Amgen Inc. (NASDAQ:AMGN) shares fell 2.39% after receiving a consensus "Hold" recommendation from analysts, with concerns raised by recent price target adjustments and insider selling that may have negatively influenced investor sentiment.

Amgen (AMGN) stock fell by 2.39% amid a competitive landscape where other companies, particularly Eli Lilly and Novo Nordisk, are experiencing substantial gains from GLP-1 drugs, indicating that Amgen may be struggling to keep pace with competitors capitalizing on the lucrative market for these innovative therapies.

Amgen (AMGN) stock experienced a decline of -0.53% due to its involvement in the highly competitive healthcare sector, which is influenced by numerous factors including innovation, regulatory changes, and market performance of peer companies like Merck and UnitedHealth, which also faced trading fluctuations.

Amgen (AMGN) stock experienced a decline of -0

Amgen (AMGN) stock rose 0.32% amid a market where investors are seeking safety in consumer staples and healthcare stocks due to ongoing volatility and economic uncertainty, with Amgen benefiting from its classification as a relatively stable investment compared to more cyclically sensitive sectors.

Amgen (AMGN) stock increased by 0.34% during the trading period, highlighting investor confidence possibly driven by the company's collaborations and advancements in biopharmaceuticals.

Amgen's stock (AMGN) fell by 2.59% as several analysts have adjusted their price targets downward and overall uncertainty in market sentiment may have contributed to the decline.

Amgen's stock (AMGN) fell by 2

Amgen (AMGN) stock rose by 0.77% as investors may have reacted positively to the disappointing clinical trial results from Novo Nordisk, which could lead to less competition in the weight-loss drug market that Amgen also targets.

Amgen (AMGN) stock rose 0.77% likely due to positive developments related to Coherus BioSciences' financial growth, including increased revenue from UDENYCA and LOQTORZI, and a strategic divestiture that positions the company well for future growth and cash flow stability.

Amgen (AMGN) stock rose by 0.39% as it is under investigation regarding potential claims related to a class-action lawsuit about undisclosed tax liabilities, which may have led to investor speculation about the company's potential outcomes.

Amgen (AMGN) stock rose by 0.39% last night, as investors are increasingly favoring healthcare stocks during trade tensions due to their resilience in economic downturns and growing demand from an aging population.

The article discusses a comparison between Generation Bio and Anthera Pharmaceuticals, noting that Generation Bio has a stronger potential upside and institutional ownership, while Amgen's (AMGN) stock rose 0.45% possibly due to its ongoing partnerships and developments in the biopharmaceutical space, which may positively influence investor sentiment.

The article discusses a comparison between Generation Bio and Anthera Pharmaceuticals, noting that G

Amgen (AMGN) stock experienced a slight decline of -0.18%, likely influenced by broader market conditions and the competitive landscape in the biotechnology sector, particularly in relation to developments from companies like BeiGene, which reported strong growth and financial results in oncology.

Amgen (AMGN) stock experienced a slight decline of -0

Amgen (AMGN) stock rose by 1.91% due to strong earnings results that exceeded analysts' expectations and a positive outlook reflected in broker ratings.

Amgen (AMGN) stock rose 2.21%, likely due to positive developments in the photodynamic therapies (PDT) market for oncology, which is projected to see significant growth attributed to an increasing number of cancer diagnoses and advancements in targeted treatments that enhance efficacy and patient outcomes.

AMGN

Latest News & Analysis